Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235
Benzinga Newsdesk 3 months ago
NewsDowngradesAnalyst RatingsPrice Target
Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.
Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.